$7.9 Billion Industry Revenue Of Drug Discovery Informatics Market by 2032

PORTLAND, OREGON, UNITED STATES, April 23, 2024 /EINPresswire.com/ -- The Drug Discovery Informatics Market is expected to grow with a significant CAGR during the analysis period mainly due to rise in chronic diseases and the advent of new powerful tools such as AI and big data. However, challenges such as inflation, supply chain issues and expiring patents might restrain the market growth.

According to the report, the drug discovery informatics market was valued at $2.9 billion in 2022, and is estimated to reach $7.9 billion by 2032, growing at a CAGR of 10.5% from 2023 to 2032.

Drug Discovery Informatics Market Overview:

Value in 2022: $2.9 billion
Projected Value by 2032: $7.9 billion
CAGR (2023-2032): 10.5%

Request Sample of the Report on Drug Discovery Informatics Market Forecast 2032: https://www.alliedmarketresearch.com/request-sample/A07074

Key Growth Drivers:

Rise in Chronic Diseases: Increased prevalence of diseases like cancer, cardiovascular diseases, diabetes, and high blood pressure.
R&D Activities: Surge in research and development for drug discovery.
Demand for Target Drug Therapy: Growing demand for specialized drug treatments.

Notable Insights:

Oncology trial starts were up by 56% from 2016 to 2021, with a focus on rare cancer indications.
30 oncology novel active substances launched globally in 2021; 159 since 2012.
Increasing research activities boost demand for clinical trials and outsourcing services.

Key Drivers:

Research Spending: Biotech and pharmaceutical companies are increasing spending on informatics.
Informatics Software: Focus on drug discovery using informatics software.
Rare Disease Research: Growing demand and support for orphan drug research.

Opportunities:

Emerging Markets: Significant growth potential in emerging markets.

Challenges:

High Costs: Expensive drug discovery informatics software.

Recession Impact:

Recession may lead to reduced R&D investments by governments, institutions, and private funders.
Pharmaceutical companies may refocus R&D on high ROI or high-demand therapeutic areas.

Market Segments & Projections:

Application (Drug Discovery): Dominated in 2022; CAGR of 10.7% expected.
Function (Sequencing & Target Data Analysis): Faster CAGR of 11.1% expected.
End Use (Pharmaceutical Companies): Dominated in 2022; CAGR of 10.8% expected.

Regional Analysis:

North America: Dominated in 2022; expected to maintain dominance.
Asia-Pacific: Faster growth expected due to rising pharmaceutical and biotech startups.

For Procurement Information - https://www.alliedmarketresearch.com/purchase-enquiry/A07074

Leading Market Players:

Certara
Boehringer Ingelheim International GmbH
Infosys Ltd.
Charles River Laboratories
Collaborative Drug Discovery, Inc.
Eurofins DiscoverX Products
Jubilant Biosys
Selvita
Novo Informatics Pvt. Ltd.
ChemAxon Ltd.
Albany Molecular Research Inc.
Oracle
Accenture
Agilent Technologies, Inc.
Illumina, Inc.

Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A07074

Similar Reports:

Computer-Aided Drug Discovery Market

Transdermal Drug Delivery Systems Market

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn